You are viewing the site in preview mode

Skip to main content

Table 2 Characteristics of the complying and non-complying groups

From: Pharmacoeconomic effect of compliance with pharmacist’s intervention based on cancer chemotherapy regimens: a cohort study

  Total n = 96 Complying group n = 58 Non-complying group n = 38 P value
Age (years) 68.6 ± 10.8 68.2 ± 10.2 69.3 ± 11.7 0.6271)
Male/female 44/52 27/31 17/21 0.9992)
History of chemotherapy (yes/no) 25/71 17/41 8/30 0.4772)
ECOG PS (0-1/2) 93/3 57/1 36/2 0.5602)
Adjuvant chemotherapy (yes/no) 7/92 6/52 1/37 0.2382)
Clinical department (number, %)     
 Surgery 25 (26.0) 18 (31.0) 7 (18.4)  
 Hematology 31 (32.3) 6 (10.3) 25 (65.8)  
 Respiratory medicine 19 (19.8) 19 (32.8) 0 (0.0)  
 Gastroenterology 11 (11.5) 7 (12.1) 4 (10.5) 0.0983)
 Gynecology 4 (4.2) 4 (6.9) 0 (0.0)  
 Urology 5 (5.2) 4 (6.9) 1 (2.6)  
 Dental surgery 1 (1.0) 0 (0.0) 1 (2.6)  
Neutrophil count (/mL) 730±245 746±286 708±240 0.371)
  1. Data are expressed as the mean SD or number (%).1)unpaired t-test, 2)Fisher’s exact test, 3)Mann–Whitney test. ECOG PS, Eastern Cooperative Oncology Group performance status. G-CSF, Granulocyte colony-stimulating factor.